Improvement effect of ranibizumab combined with half-volume ciliary body photocoagulation on visual acuity and intraocular pressure in NVG
Objective To explore the improvement effect of ranibizumab combined with half-volume ciliary body photocoagulation in the treatment of neovascular glaucoma(NVG).Method A total of 110 patients(110 eyes)with NVG treated in the hospital were enrolled as the research objects between January 2021 and January 2023.They were divided into two groups,55 cases in each group.The control group was treated with half-volume ciliary body photocoagulation,while observation group was additionally treated with leizumab once a month for 3 consecutive times.The disappearance time of neovascularization,success rate of treatment,postoperative complications,recurrence rate at 6 months after surgery,BCVA,intraocular pressure,IL-1β,IL-1β,IL-6 and VEGF were compared before and after treatment.Result The success rate of neovascularization time and recurrence rate 6 months after operation in the observation group were better than those in the control group(P<0.05).At 1 month,3 months and 6 months after treatment,BCVA in both groups was significantly increased(P<0.05).After treatment,intraocular pressure in both groups was significantly decreased,which was lower in observation group(P<0.05).After treatment,levels of IL-1β,IL-6 and VEGF in both groups were decreased,which were lower in observation group(P<0.05).Conclusion Ranibizumab combined with half-volume ciliary body photocoagulation had high success rate in the treatment of NVG,which could effectively improve intraocular pressure and inflammation level,and reduce postoperative recurrence rate.
Neovascular glaucomaRanibizumabHalf-volume ciliary body photocoagulationVisual acuityIntraocular pressure
万方数据
维普
